ADAMTS9-AS2 and central nervous system cancer: In addition, DNMT1 expression was inversely correlated with MEG3 transcript, supporting DNMT1's involvement in MEG3 dysregulation in glioma.61 Importantly, the same association of MEG3 expression with promoter methylation status has been observed in hepatocellular cancer, and direct involvement of miR‐29a, a DNMT1 and DNMT3B epigenetic modulator, was also demonstrated.90 The activity of tumour suppressor ADAMTS9‐AS2 is also controlled by DNA methylation in glioma.